MX363119B - Composicion farmaceutica. - Google Patents
Composicion farmaceutica.Info
- Publication number
- MX363119B MX363119B MX2014013091A MX2014013091A MX363119B MX 363119 B MX363119 B MX 363119B MX 2014013091 A MX2014013091 A MX 2014013091A MX 2014013091 A MX2014013091 A MX 2014013091A MX 363119 B MX363119 B MX 363119B
- Authority
- MX
- Mexico
- Prior art keywords
- insulin
- subject
- compound
- combination
- administration
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 7
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 7
- 230000002608 insulinlike Effects 0.000 abstract 7
- 230000002641 glycemic effect Effects 0.000 abstract 4
- 102000004877 Insulin Human genes 0.000 abstract 3
- 108090001061 Insulin Proteins 0.000 abstract 3
- 230000009286 beneficial effect Effects 0.000 abstract 3
- 229940125396 insulin Drugs 0.000 abstract 3
- 235000012054 meals Nutrition 0.000 abstract 3
- 102000016261 Long-Acting Insulin Human genes 0.000 abstract 2
- 108010092217 Long-Acting Insulin Proteins 0.000 abstract 2
- 229940100066 Long-acting insulin Drugs 0.000 abstract 2
- 125000000729 N-terminal amino-acid group Chemical group 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 239000004026 insulin derivative Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se describe una combinación que comprende por lo menos un primer compuesto similar a insulina y un segundo compuesto similar a insulina para tratar una condición o una enfermedad en un sujeto en necesidad del mismo en donde la administración de insulina puede ser de beneficio para el sujeto. La combinación se administra en una cantidad para obtener un control glucémico benéfico en el sujeto determinado por los valores de HbA1c en el sujeto después de administración de la combinación en el alimento más grande del día para el sujeto; en donde el control glucémico benéfico por la combinación es superior a cualquier control glucémico obtenido por una dosis equivalente de IGlar en el sujeto, determinada por los niveles de HbA1c en el sujeto después de administración de IGlar para el sujeto y/o en donde el control glucémico benéfico por la combinación comprende disminuir los niveles de HbA1c en el sujeto a aproximadamente 7 o menos después de administración de la combinación en el alimento más grande del día, en donde el primer compuesto similar a insulina tiene una acción más prolongada que el segundo compuesto similar a insulina; en donde la combinación se administra en el alimento más grande del día para el sujeto; en donde el primer compuesto similar a insulina es por lo menos una insulina de acción prolongada, preferiblemente una insulina de acción ultraprolongada; en donde el primer compuesto similar a insulina es un derivado de una insulina como se encuentra de modo natural o es un análogo de insulina; y en donde el primer compuesto similar a insulina tiene una cadena lateral unida al grupo alfa-amino del residuo aminoácido N-terminal de la cadena B o al grupo e-amino de un residuo Lys presente en la cadena B de la insulina original, la cadena lateral es de la fórmula (I) W-X-Y-Z.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12166252 | 2012-05-01 | ||
| EP12166251 | 2012-05-01 | ||
| US201261641544P | 2012-05-02 | 2012-05-02 | |
| US201261641540P | 2012-05-02 | 2012-05-02 | |
| PCT/EP2013/059073 WO2013164375A1 (en) | 2012-05-01 | 2013-05-01 | Pharmaceutical composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014013091A MX2014013091A (es) | 2014-12-08 |
| MX363119B true MX363119B (es) | 2019-03-11 |
Family
ID=49514218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014013091A MX363119B (es) | 2012-05-01 | 2013-05-01 | Composicion farmaceutica. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9884094B2 (es) |
| EP (1) | EP2844274B1 (es) |
| JP (1) | JP6262206B2 (es) |
| AU (1) | AU2013255880B2 (es) |
| BR (1) | BR112014026442A8 (es) |
| CA (1) | CA2872083A1 (es) |
| MX (1) | MX363119B (es) |
| RU (1) | RU2670106C2 (es) |
| WO (1) | WO2013164375A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090074882A1 (en) | 2005-12-28 | 2009-03-19 | Novo Nordisk A/S | Insulin compositions and method of making a composition |
| JP6049625B2 (ja) | 2010-10-27 | 2016-12-21 | ノヴォ ノルディスク アー／エス | 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療 |
| CN105188736A (zh) * | 2013-03-20 | 2015-12-23 | 诺和诺德股份有限公司 | 胰岛素给药方案 |
| WO2014177623A1 (en) * | 2013-04-30 | 2014-11-06 | Novo Nordisk A/S | Novel administration regime |
| WO2016001185A1 (en) * | 2014-07-02 | 2016-01-07 | Novo Nordisk A/S | Dosage regimen for the treatment of diabetes |
| US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
| CN114096269B (zh) | 2019-07-12 | 2024-06-11 | 诺和诺德股份有限公司 | 高浓度胰岛素制剂 |
| US20250154220A1 (en) * | 2023-11-15 | 2025-05-15 | Ambio, Inc. | Insulin analogs for the treatment of human metabolic disorder and disease |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH25772A (en) | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
| NZ222907A (en) | 1986-12-16 | 1990-08-28 | Novo Industri As | Preparation for intranasal administration containing a phospholipid absorption enhancing system |
| HUT56857A (en) | 1988-12-23 | 1991-10-28 | Novo Nordisk As | Human insulin analogues |
| IL93282A (en) | 1989-02-09 | 1995-08-31 | Lilly Co Eli | Insulin analogues |
| WO1990013540A1 (en) | 1989-04-19 | 1990-11-15 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| SI0792290T1 (en) | 1993-09-17 | 2001-12-31 | Novo Nordisk As | Acylated insulin |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US6531448B1 (en) * | 1997-12-23 | 2003-03-11 | Eli Lilly And Company | Insoluble compositions for controlling blood glucose |
| KR101186851B1 (ko) | 2003-08-05 | 2012-10-02 | 노보 노르디스크 에이/에스 | 신규의 인슐린 유도체 |
| KR101159559B1 (ko) | 2003-08-05 | 2012-06-26 | 노보 노르디스크 에이/에스 | 신규의 인슐린 유도체 |
| US20090074882A1 (en) | 2005-12-28 | 2009-03-19 | Novo Nordisk A/S | Insulin compositions and method of making a composition |
| EP2015770B1 (en) | 2006-05-09 | 2012-09-26 | Novo Nordisk A/S | Insulin derivative |
| WO2008152106A1 (en) | 2007-06-13 | 2008-12-18 | Novo Nordisk A/S | Pharmaceutical formulation comprising an insulin derivative |
| EP2242767A4 (en) * | 2008-02-19 | 2011-04-06 | Biocon Ltd | PROCESS FOR OBTAINING PURIFIED HETEROLOGOUS INSULINS EXPRESSED IN YEASTS |
| CA2738615A1 (en) * | 2008-10-30 | 2010-05-06 | Novo Nordisk A/S | Treating diabetes melitus using insulin injections with less than daily injection frequency |
| SI2632478T1 (sl) * | 2010-10-27 | 2019-11-29 | Novo Nordisk As | Zdravljenje sladkorne bolezni z uporabo inzulinskih injekcij, ki se dajejo v različnih injicirnih intervalih |
-
2013
- 2013-05-01 WO PCT/EP2013/059073 patent/WO2013164375A1/en not_active Ceased
- 2013-05-01 JP JP2015509430A patent/JP6262206B2/ja active Active
- 2013-05-01 EP EP13721650.3A patent/EP2844274B1/en active Active
- 2013-05-01 BR BR112014026442A patent/BR112014026442A8/pt not_active Application Discontinuation
- 2013-05-01 MX MX2014013091A patent/MX363119B/es unknown
- 2013-05-01 AU AU2013255880A patent/AU2013255880B2/en active Active
- 2013-05-01 US US14/398,018 patent/US9884094B2/en active Active
- 2013-05-01 CA CA 2872083 patent/CA2872083A1/en not_active Withdrawn
- 2013-05-01 RU RU2014147674A patent/RU2670106C2/ru active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2844274A1 (en) | 2015-03-11 |
| JP6262206B2 (ja) | 2018-01-17 |
| EP2844274B1 (en) | 2019-03-20 |
| AU2013255880B2 (en) | 2017-07-20 |
| WO2013164375A1 (en) | 2013-11-07 |
| AU2013255880A1 (en) | 2014-10-16 |
| CA2872083A1 (en) | 2013-11-07 |
| MX2014013091A (es) | 2014-12-08 |
| US20150126439A1 (en) | 2015-05-07 |
| US9884094B2 (en) | 2018-02-06 |
| BR112014026442A2 (pt) | 2017-06-27 |
| JP2015517458A (ja) | 2015-06-22 |
| RU2014147674A (ru) | 2016-06-27 |
| BR112014026442A8 (pt) | 2018-01-16 |
| RU2670106C2 (ru) | 2018-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX363119B (es) | Composicion farmaceutica. | |
| PH12019500517A1 (en) | Long-acting formulations of insulins | |
| PH12014500922A1 (en) | Insulinotropic peptide derivative wherein its n-terminal amino acid is modified | |
| MX366906B (es) | Purificacion de iduronato-2-sulfatasa. | |
| MX2022004041A (es) | Derivados de oxintomodulina novedosos y composicion farmaceutica para tratar la obesidad que comprende los mismos. | |
| MX375745B (es) | Composicion para el tratamiento de la diabetes que comprende conjugado de analogo de insulina de accion prolongada y conjugado de peptido insulinotropico de accion prolongada. | |
| SG178797A1 (en) | Oligosaccharide chain added glp-1 peptide | |
| EP4434350A3 (en) | Feed additive composition | |
| MY183793A (en) | Pharmaceutical compositions | |
| MX376269B (es) | Composición que comprende nanopartículas, preparación y su uso en la preparación de un fármaco para el tratamiento del cáncer. | |
| UA117480C2 (uk) | Лікування цукрового діабету за допомогою складу інсуліну тривалої дії | |
| WO2011087835A3 (en) | Novel compositions and methods for treating inflammatory bowel disease and airway inflammation | |
| NZ602380A (en) | Peptides for vaccine against birch allergy | |
| AU2012207301A8 (en) | Apolipoprotein AIV as an antidiabetic peptide | |
| MX2012010520A (es) | Composicion antioxidante para reducir el estres oxidativo atribuible al tratamiento con farmacos anticonceptivos hormonales. | |
| WO2013084070A3 (en) | Salmonella vaccine proteins | |
| NZ707168A (en) | Pharmaceutical composition of insulins | |
| HK1203392A1 (en) | Composition containing antibodies against gluten and tannins | |
| BR112013000296A2 (pt) | agentes terapêuticos 976 | |
| WO2015083114A3 (en) | Biologically active insulin derivatives | |
| MX2015013160A (es) | Metodo y productos para mejorar la absorcion celular de farmaco y suplementos dieteticos. | |
| RU2010126053A (ru) | Применение аналогов соматостатина при менингиоме | |
| HK1229209A1 (en) | Method and products for enhancing cellular uptake of drug and dietary supplements | |
| IN2013MU01156A (es) | ||
| IN2013MU01157A (es) |